New oral anticoagulants for the prevention of stroke: Open questions in geriatric patients;Neue Orale Antikoagulanzien Zur Schlaganfallprävention: Offene Fragen bei geriatrischen Patienten

Zeitschrift fur Gerontologie und Geriatrie

Volumn 45, Issue 6, 2012, Pages 498-504

  Berthold, H K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antithrombotic agents; Atrial fibrillation; Dabigatran; Rivaroxaban; Vitamin.k antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MORPHOLINES; STROKE; THIOPHENES;

EID: 84865788694     PISSN: 09486704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00391-012-0377-4     Document Type: Article

References (27)

1. Artang R, Rome E, Vidaillet H (2012) Dabigatran and myocardial infarction, drug or class effect. Meta-analysis of randomized trials with oral direct thrombin inhibitors. J Am Coll Cardiol 59:E571
2. Beasley BN, Unger EF, Temple R (2011) Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 364:1788-1790
3. Buckingham TA, Hatala R (2002) Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 25:447-454
4. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369-2429
5. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
6. Connolly SJ, Ezekowitz MD, Yusuf S et al (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875-1876
7. Diener HC, Connolly SJ, Ezekowitz MD et al (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9:1157-1163
8. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573-1579
9. Eikelboom JW, Wallentin L, Connolly SJ et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363-2372
10. Freeman JV, Zhu RP, Owens DK et al (2011) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154:1-11
11. Gage BF, Yan Y, Milligan PE et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713-719
12. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
13. Harper P, Young L, Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864-866
14. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857-867
15. Heneghan C, Alonso-Coello P, Garcia-Alamino JM et al (2006) Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367:404-411
16. Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50:2156-2161
17. Horn J, Hanston P (2010) Dabigatran: a new oral anticoagulant. Pharmacy Times 12:59
18. Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019-1026
19. Kassenärztliche Vereinigung Nordrhein (2011) Verordnungshinweis Dabigatran (Pradaxa) bei Vorhofflimmern. Verordnungsinfo Nordrhein 01.09.2011
20. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
21. Pink J, Lane S, Pirmohamed M, Hughes DA (2011) Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343:d6333
22. Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093-1100
23. Poli D, Antonucci E, Testa S et al (2011) Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 124:824-829
24. Ruff CT, Giugliano RP, Antman EM et al (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635-641
25. Sorensen SV, Kansal AR, Connolly S et al (2011) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 105:908-919
26. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397-402
27. Wittkowsky AK (2004) Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care 10:297-306